Launch of LAL-Deficiency Knowledge Centre
The Lysosomal Acid Lipase Deficiency (LAL-D) Knowledge Centre has now launched on Medthority.com, intended for healthcare professionals involved in the treatment and management of patients with this condition.
LAL deficiency is an autosomal recessive lysosomal storage disorder resulting in marked lysosomal accumulation of cholesteryl esters and triglycerides. The two major phenotypes of this condition are an early onset phenotype primarily affecting infants (formerly known as Wolman disease), and a late onset phenotype – also called cholesteryl ester storage disease (CESD).
Users of this educational resource can expect to find clinical content arranged within three main sections:
Disease Awareness: including epidemiology, pathophysiology, genotypic presentation, diagnosis, prognosis and more…
Treatment: presents the drug characteristics, safety and efficacy of Sebelipase alfa – the first and only licenced treatment for LAL-deficiency
Resources: useful external links, events calendar and a video channel with short expert video discussions on topics such as diagnostic approach and current prognosis.
Developed by EPG Health Media (Europe) Ltd for Medthority.com, in collaboration and with content provided by Alexion Pharma GmbH
Related news and insights
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.